---
title: 'Paroxysmal nocturnal hemoglobinuria-related thrombosis in the era of novel
  therapies: a 2043 patient/years analysis'
date: '2024-03-21'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38513233/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240322180500&v=2.18.0.post9+e462414
source: Blood
description: Thrombophilia is one of the principal features of paroxysmal nocturnal
  hemoglobinuria (PNH) and constitutes the main cause of disease morbidity/mortality.
  Anti-complement treatment has revolutionized the natural history of PNH with control
  of the hemolytic process and abolition of thrombotic events (TE). However, no guidelines
  exist for the management of thromboembolic complications in this setting, with type
  and duration of anti-coagulation depending on individual practices. Besides, a ...
disable_comments: true
---
Thrombophilia is one of the principal features of paroxysmal nocturnal hemoglobinuria (PNH) and constitutes the main cause of disease morbidity/mortality. Anti-complement treatment has revolutionized the natural history of PNH with control of the hemolytic process and abolition of thrombotic events (TE). However, no guidelines exist for the management of thromboembolic complications in this setting, with type and duration of anti-coagulation depending on individual practices. Besides, a ...